
- Share on:
- Bio-rad Twitter
- Bio-rad Facebook
- Bio-rad LinkedIn
Quantifying AAV Viral Titers to Support AAV-Based Gene Therapy Development
Droplet Digital™ PCR (ddPCR™) can provide an absolute count of nucleic acids in a sample without using a standard curve. Learn how ddPCR technology offers the accuracy to quantify AAV viral titers to support many aspects of quality control for AAV-based gene therapy development. In addition to accurate measurement of AAV titer for proper dosing, ddPCR technology can detect other critical quality attributes, including residual host cell DNA and other contaminants.
What you will find in this article:
- A review of challenges and risks in the development of gene therapies
- How ddPCR technology can help developers of AAV-based therapies mitigate these risks
- Key references on the role of ddPCR technology in cell and gene therapy

Download the Article
Share a little information with us to access the entire article now.
Thank you for your interest in ! Access the article here.
View ArticleContent you'll also find interesting
Recommended Features
-
Image
Transitioning Your Assay from Quantitative PCR to Droplet Digital™ PCR
Get guidance on how to transition from qPCR to ddPCR technology and the differences to consider between the two methods based on AAV titering assay study.
-
Image
From Concept to Cure: Using AAV in Gene Therapy
Use this guide to learn about AAV vector challenges, AAV characterization, and addressing developmental hurdles of using vectors in gene therapy.
-
Image
Measuring AAV Vector Genome Titer Using Droplet Digital™ PCR Protocol
Get started with this protocol designed to measure AAV vector genome titer using ddPCR technology for both in-process and purified samples.